Utilising a Virtual Central Laboratory Approach to Balance the Delivery, Budget and Risk for Clinical Trials
About this webinar
Decentralisation has been one of the biggest outcomes of the COVID-19 pandemic. The speed and degree to which traditional healthcare providers were overwhelmed by the sudden influx of critically ill patients, and the disruption to even local travel, meant that if clinical trials were to continue, they had to adapt, and fast.
Many small to mid-sized pharmaceutical and biotech companies, having adjusted to their own “new normal” day-to-day, are also now realising that there are other options to analysing clinical trials samples than the traditional central lab approach. Ongoing challenges, such as Brexit, driver shortages, the Suez blockade, and potentially dry ice shortages have forced people to adopt a “new normal” to achieve their analytical results.
By decentralising the central laboratory testing for late phase I or phase II clinical trials, milestones can be kept on track and cost effectiveness of the study improved.
Register for this webinar in which featured speakers will discuss:
- Utilising a network of smaller local laboratories for basic safety analysis so that critical data is available to investigators in real time
- Balancing complex laboratory analysis requirements with inflexible laboratory processes
- Navigating rigid laboratory analysis schedules
- Dealing with unanticipated roadblocks
Who should attend
- Investigators
- Clinical drug developers
- Pharma companies
- Biotechs
- CMOs
- CEOs
What you will learn
- Saving time
- Reducing budget
- Increasing the ability to navigate unanticipated difficulties
Featured Speakers
Mike Fudge
Mike has 15 years’ experience in the drug development process, predominately in lab operations management, including sample management, across the globe. He has driven business transformation through large and small organisations, defining and managing large programs for lab digitization, lab automation and process optimization.
Dr. Debra Davies
Dr. Davies has been leading small to midsize pharma clients through the analytical requirements of GCP clinical trials for over 35 years. She is experienced in developing and running hundreds of methods across a breadth of techniques. Currently, she is heading up innovation and development to transform clients’ requirements into an analytical strategy.
Partner for this event
Simbec-Orion
Simbec-Orion is a responsive and agile full-service CRO, with wide therapeutic experience and specialist expertise in clinical pharmacology, oncology and rare diseases. Simbec-Orion offers clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post-marketing studies. With a focus on tailormade and scalable solutions, Simbec-Orion adapt delivery style, communications and operations to suit the demands of your project, helping you achieve your clinical and commercial objectives.
Related webinars
More from Simbec-Orion.
Embedding Neuroscience Techniques to Measure Target Engagement in First-In-Human CNS Clinical Trials
Accelerate Early Clinical Development with Adaptive, Multi-Part, First-in-Human Study Design
Meeting the Needs of Rare Disease Patients in Clinical Trials During the COVID-19 Pandemic
Time for a Clinical Trial Revolution – Complex Innovative Design (CID) Cancer Trials
Phase I Studies in Patient Populations: De-risking Clinical Development by Obtaining Key Patient Data Earlier
Agility in Rare Disease and Oncology Clinical Trials – Data Management
Providing Critical Data in Early Clinical Development with Scintigraphy
ESMO Update: State of the Art in Early Phase Oncology Trial Design
Orphan Drug Designation: Meeting the Unmet Need in Rare Diseases
Effective Implementation of the Revised EMA First-in-Human (FIH) Guidance to Accelerate Your Early Clinical Development
Conducting Early Phase Oncology Studies – Successfully Moving Through to Proof of Concept and Beyond
Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn
